Evidence map›Paper›PMID 41894587›Full record

ArticleStem cells translational medicine2026

Dynamic immune reconstitution and clinical outcomes in different chimerism statuses of HLA-matched transplantation for severe aplastic anemia.

Ming-Hao Lin, Zheng-Li Xu, Ying-Jun Chang, Hui-Dong Guo, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Yi-Fei Cheng, Yuan-Yuan Zhang, Xiao-Dong Mo and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ming-Hao LinPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Zheng-Li XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Ying-Jun ChangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Hui-Dong GuoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yi-Fei ChengPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yuan-Yuan ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Xiao-Dong MoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yu-Qian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.ORCID 0000-0003-1856-2231
Ting-Ting HanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.ORCID 0000-0001-5047-9249
Jing-Zhi WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yao ChenPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yu-Hong ChenPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Huan ChenPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Wei HanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.ORCID 0000-0002-2145-6643

Funding

Key Program of the National Natural Science Foundation of China 82530009Major Program of the National Natural Science Foundation of China 82293630National Key Research and Development Program of China 2022YFA0103300
6 · The paper itself

Abstract

This retrospective study examines the clinical outcomes and immune reconstitution dynamics in patients with severe aplastic anemia (SAA) exhibiting mixed chimerism (MC) compared with those with full donor chimerism (FDC) following HLA-matched hematopoietic stem cell transplantation (HSCT). Analysis of propensity score-matched cohorts (23 MC vs 69 FDC) revealed comparable 5-year overall survival (OS: 87.0% vs 92.8%, P = .433) but significantly inferior failure-free survival (FFS: 47.8% vs 87.0%, P < .001) in patients with MC due to a higher incidence of graft failure (52.2% vs 8.7%, P < .001). Longitudinal immune profiling revealed delayed recovery of myeloid and lymphoid lineages in patients with MC at 12 months post-HSCT, with pronounced deficits in adaptive immunity. Specifically, CD8+CD28+ T cell counts were consistently reduced at 1 month (median, 20 vs 41 cells/μL, P = .049), 3 months (median, 86 vs 153 cells/μL, P = .024), and 6 months (median, 109 vs 160 cells/μL, P = .001), and CD4+CD25+ T cells were diminished at 6 months (median, 11 vs 20 cells/μL, P = .006). Multivariate analysis revealed that elevated CD8+CD28+ T cell levels at 3 months (≥140 cells/μL) were an independent predictor of improved FFS (HR = 0.30, P = .035). These findings highlight MC-associated immune dysregulation, particularly impaired CD28-costimulated T cell and CD4+CD25+ T cell reconstitution, as a key mediator of graft instability. This study underscores the prognostic value of early immune monitoring and suggests therapeutic strategies that target T cell recovery to mitigate MC-related risk in patients with SAA.

Indexed as

Anemia, AplasticHematopoietic Stem Cell TransplantationHLA AntigensImmune ReconstitutionTransplantation ChimeraAdolescentAdultChildFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultHLA Antigensfull donor chimerismHLA-matched transplantationimmune reconstitutionmixed chimerismsevere aplastic anemia

Identifiers

PMID41894587
PMCPMC13026414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.